GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that the Arexvy vaccine (MAL24086007ARZ) has been approved in Malaysia for respiratory syncytial virus (RSV). RSV is a common respiratory ...
Insurance companies could be required to cover asthma inhalers at no cost in New York state. Assemblywoman Jessica ...
The "Typhoid Fever - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.Comprehensive insights into the future of typhoid fever treatment are now available, exploring ...
Insurance companies could be required to cover asthma inhalers at no cost in New York state. Assemblywoman Jessica ...
Antibiotic resistance is a threat to modern healthcare. Nine European research projects have published in Nature Reviews Drug Discovery an article emphasizing the need to maintain expertise and ...
DoctorsOfJoy aims to highlight how dentists empower individuals to fully enjoy life's moments by addressing oral health ...
Falak is a newly built Grade A office building located in the heart of Dubai Internet City (DIC), offering over 90,000 square ...
On3 on MSN2h
Report: FedEx continuing to reduce sponsorship presence with Joe Gibbs Racing, could sever ties altogetherFedEx is reportedly set to continue reducing its sponsorship presence with Joe Gibbs Racing after this season, with the ...
Investors will look forward to the Nifty hitting psychologically crucial 26,000 mark. Catch the latest on Indian equity ...
The stock jumped more than 12% to hit its lifetime high of Rs 7,598. The surge was as the company received Central Drugs ...
Arexvy has been approved in Malaysia for RSV (respiratory syncytial virus), for older adults aged 60 and above. The vaccine ...
Cancer Vaccines Market revenue is expected to hold around USD 24.22 billion by 2033 from USD 9 million in 2023 with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback